RSPI - RespireRx Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0120
-0.0010 (-7.69%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.0130
Open0.0130
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0080 - 0.0150
52 Week Range0.0080 - 0.8500
Volume545,595
Avg. Volume93,537
Market Cap62,336
Beta (5Y Monthly)-0.75
PE Ratio (TTM)N/A
EPS (TTM)-0.5640
Earnings DateApr 13, 2020 - Apr 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.30
  • RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.

    Glen Rock, N.J., March 04, 2020 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a.

  • RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report

    RespireRx Pharmaceuticals Inc. (RSPI), a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”) indications, with a focus on obstructive sleep apnea, attention deficit hyperactivity disorder (“ADHD”), spinal cord injury and other neurological conditions, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties. To build out the neuromodulator program, we are considering the addition of non-ampakine neuromodulators to the platform.

  • RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications

    Specific claims cover low cannabinoid dosage strengths and controlled release formulations for attaining a desired therapeutic window of cannabinoid blood levels that produces the desired therapeutic effect(s) for a controlled period of time, while minimizing undesirable side effects. Additional claims include cannabinoid compositions and methods for treating cannabinoid-sensitive disorders, including sleep apnea, pain, glaucoma, muscle spasms, anorexia and other conditions.

  • RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors

    Tim Jones is a highly experienced biopharmaceutical industry veteran with an outstanding track record in strategic commercial and business development, specializing in developing and sustaining high value strategic partnerships. This business was spun off as Purisys, LLC which focuses on cannabinoids for pharmaceutical and consumer products.

  • RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit

    Executive Chairman/CSO/Interim CEO participating as a workshop leader on Cannabinoid Formulations-Which Technology to Select for Pre & Clinical Assessments? Glen Rock, N.J, Sept. 09, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of medicines that promote neuronal signaling in diseases and disorders of neuronal dysfunction, is pleased to announce that members of its executive management team are participating at the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit at the Aloft Boston Seaport District, 401-403 D. St. Boston, MA.

  • RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD.
    GlobeNewswire

    RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD.

    RespireRx Pharmaceuticals Inc. (RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, announces that it has sent a formal notice to the Board of Directors of Therapix Biosciences Ltd. (Therapix). In public disclosures on the Therapix’ website and in its press releases (most recently on July 23, 2019), Therapix has repeatedly made public statements that it intends to develop THX-110, a combination of dronabinol and PEA, for treating obstructive sleep apnea (OSA) in the United States and other markets. RespireRx Pharmaceuticals Inc (RespireRx) has licensed and is in possession of patents and patent applications for treating any sleep related breathing disorder, including OSA, using any cannabinoid alone or in combination with any other molecule or drug.

  • RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia

    RespireRx Pharmaceuticals Inc. (RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that it has entered into a non-binding memorandum of understanding (“MOU”) and exclusivity agreement with Impression Healthcare Limited (IHL.AX)(“Impression”) for the purpose of negotiating terms by which the parties would enter in an arrangement, such as a license, joint venture or partner agreement, so as to commercialize dronabinol for the treatment of OSA in Australia, New Zealand and Southeast Asia. OSA, a sleep-related breathing disorder characterized by interrupted breathing, represents a significant global health challenge that increases the risk of health problems, including diabetes, cardiovascular disease and mental disorders.

  • RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors

    RespireRx Pharmaceuticals Inc. (RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of medicines that promote neuronal signaling in diseases and disorders of neuronal dysfunction, is pleased to announce the promotion of James Sapirstein to Executive Vice Chairman of the Board of Directors effective December 28, 2018. Mr. Sapirstein, who has served as a member of the Board of Directors since 2014, expands his role within RespireRx to assist with business development and fundraising activities to advance the development of the company’s pipeline of neuromodulators with a focus on sleep apnea, as well as neurologic and psychiatric disorders.

  • RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
    GlobeNewswire

    RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

    RespireRx Pharmaceuticals Inc. (RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of medicines that promote neuronal signaling in diseases and disorders of neuronal dysfunction, is pleased to announce that the Company and members of its executive management team are highlighted speakers at the International Cannabinoid Derived Pharmaceuticals Summit at the Revere Hotel, 200 Stuart St. Boston, MA (http://international-cdp.com/). Richard Purcell, RespireRx Senior Vice President of Research & Development will co-lead a workshop on December 10th on “Financial Planning and Commercial Strategy” for cannabinoids.